On December 15, 2016, the United States Court of Appeals for the Eleventh Circuit affirmed the dismissal of a securities class action against Galectin Therapeutics Inc., a Georgia-based biotechnology company. The suit...more
12/21/2016
/ Disclosure Requirements ,
Financial Markets ,
Pharmaceutical Industry ,
Public Offerings ,
Publicly-Traded Companies ,
Rule 10(b) ,
Securities ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Securities Violations ,
Stock Promoters ,
Stocks ,
Third-Party Agents